Displaying drugs 26 - 50 of 136 in total
| DrugBank ID | Name CAS Number |
Weight Formula |
Structure | Categories | Therapeutic Indication |
|---|---|---|---|---|---|
| DB00106 |
Abarelix
183552-38-7 |
1416.0630 C72H95ClN14O14 |
|
Anti-Testosterone Agents / Antineoplastic Agents | For palliative treatment of advanced prostate cancer. |
| DB00111 |
Daclizumab
152923-56-3 |
142612.1000 C6332H9808N1678O1989S42 |
|
Immunomodulatory Agents / Immunosuppressive Agents | Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection |
| DB00028 |
Intravenous Immunoglobulin
9007-83-4 |
142682.3000 C6332H9826N1692O1980S42 |
|
Anti-Infectives / Immunomodulatory Agents | IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thromb... |
| DB00078 |
Ibritumomab
174722-31-7 |
143375.5000 C6382H9830N1672O1979S54 |
|
Antineoplastic Agents | For treatment of non-Hodgkin's lymphoma |
| DB00074 |
Basiliximab
152923-56-3 |
143801.3000 C6378H9844N1698O1997S48 |
|
Immunomodulatory Agents / Immunosuppressive Agents | For prophylactic treatment of kidney transplant rejection |
| DB00073 |
Rituximab
174722-31-7 |
143859.7000 C6416H9874N1688O1987S44 |
|
Antineoplastic Agents | For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. |
| DB00081 |
Tositumomab
192391-48-3 |
143859.7000 C6416H9874N1688O1987S44 |
|
Antineoplastic Agents | For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) |
| DB00051 |
Adalimumab
331731-18-1 |
144190.3000 C6428H9912N1694O1987S46 |
|
Antirheumatic Agents / Immunomodulatory Agents | For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. |
| DB00065 |
Infliximab
170277-31-3 |
144190.3000 C6428H9912N1694O1987S46 |
|
Immunomodulatory Agents / Immunosuppressive Agents | To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ... |
| DB00020 |
Sargramostim
83869-56-1 |
14434.5000 C639H1006N168O196S8 |
|
Immunomodulatory Agents / Antineoplastic Agents / Anti-Infective Agents | For the treatment of cancer and bone marrow transplant |
| DB00113 |
Arcitumomab
154361-48-5 |
144482.5000 C6398H9900N1714O1995S54 |
|
Diagnostic Agents / Imaging Agents | For imaging colorectal tumors |
| DB00043 |
Omalizumab
242138-07-4 |
145058.2000 C6450H9916N1714O2023S38 |
|
Anti-Asthmatic Agents / Immunomodulatory Agents | For treatment of asthma caused by allergies |
| DB06168 |
Canakinumab
914613-48-2 |
145200.0000 C6452H9958N1722O2010S42 |
|
Investigated for use/treatment in rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory disorders (unspecified), and autoimmune diseases. | |
| DB00087 |
Alemtuzumab
216503-57-0 |
145453.8000 C6468H10066N1732O2005S40 |
|
Antineoplastic Agents | Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
| DB00072 |
Trastuzumab
180288-69-1 |
145531.5000 C6470H10012N1726O2013S42 |
|
Antineoplastic Agents | For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2. |
| DB00054 |
Abciximab
143653-53-6 |
145651.1000 C6462H9964N1690O2049S48 |
|
Anticoagulants / Antiplatelet Agents | Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergo... |
| DB00002 |
Cetuximab
205923-56-4 |
145781.6000 C6484H10042N1732O2023S36 |
|
Antineoplastic Agents | For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetux... |
| DB00075 |
Muromonab
140608-64-6 |
146189.7000 C6460H9946N1720O2043S56 |
|
Immunomodulatory Agents / Immunosuppressive Agents | For treatment of organ transplant recipients, prevention of organ rejection |
| DB08879 |
Belimumab
356547-88-1 |
147 kDa C 6358 H 9904 N 1728 O 2010 S 44 |
|
Monoclonal Antibody / Immunosuppressive Agents | Adjunct treatment of autoantibody-positive active systemic lupus erythematosus |
| DB01257 |
Eculizumab
219685-50-4 |
148000.0000 |
|
For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. | |
| DB00083 |
Botulinum Toxin Type A
93384-43-1 |
149322.7000 C6760H10447N1743O2010S32 |
|
Anti-Wrinkle Agents / Antidystonic Agents / Neuromuscular Blocking Agents | For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia... |
| DB00042 |
Botulinum Toxin Type B
93384-44-2 |
150804.0000 |
|
Antidystonic Agents | For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. |
| DB00041 |
Aldesleukin
85898-30-2 |
15314.8000 C690H1115N177O202S6 |
|
Antineoplastic Agents | For treatment of adults with metastatic renal cell carcinoma. |
| DB00039 |
Palifermin
162394-19-6 |
16192.7000 C721H1142N202O204S9 |
|
Antimucositis Agents | For treatment of oral mucositis associated with chemotherapy and radiation therapy. |
| DB00080 |
Daptomycin
103060-53-3 |
1620.6706 C72H101N17O26 |
|
Anti-Bacterial Agents | For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms. |
Displaying drugs 26 - 50 of 136 in total